Joint Symposium on Medicinal Chemistry Frontiers
Optional Excursions
Registration
Opening of the Symposium & Welcome Address
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Session Chair
Prof. Katarzyna KIEC-KONONOWICZ
JAGIELLONIAN UNIVERSITY, Krakow, Poland
Derivatives of 1,3,5-triazine as a New Trend in the Search for the 5-HT6 Receptor Ligands with Therapeutic Perspectives (PL01)
Dr Jadwiga HANDZLIK
MEDICAL COLLEGE OF JAGIELLONIAN UNIVERSITY, Krakow, Poland
Welcome Reception
Registration
Session Chair
Prof. Krzysztof JOZWIAK
MEDICAL UNIVERSITY OF LUBLIN, Lublin, Poland
Libraries of Fluorogenic Substrates with Natural and Unnatural Amino Acids as a Tool in Design of Active and Specific Probes for Investigation of Proteolytic Enzymes (IL01)
Prof. Marcin DRAG
WROCLAV UNIVERSITY OF TECHNOLOGY, Wroclaw, Poland
MMP-9 at the Synapse in the Brain and Mind (IL02)
Prof. Leszek KACZMAREK
NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY, Warsaw, Poland
Metalloproteinase Cleavage Control of Interferon Alpha and Gamma Dampens Inflammation and Anti-Viral Immunity (IL03)
Prof. Christopher OVERALL
UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada
Coffee Break and Exhibition
Session Chair
Prof. Terry MOORE
UNIVERSITY OF ILLINOIS, Chicago, United States
Designing Synthetic Gene Regulators (SynGRs) (IL04)
Prof. Aseem ANSARI
UNIVERSITY OF WISCONSIN-MADISON, Madison, United States
Exploring Bacterial Genomes for Natural Product Discovery and Development (IL05)
Prof. Alessandra S. EUSTAQUIO
UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, United States
Integrative Screening Identifies a Novel Node in the Oncogenic YAP/HIPPO Pathway (IL06)
Dr Mathias FREDERIKSEN
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (NIBR), Basel, Switzerland
Lunch and Exhibition
Session Chair
Prof. Daniel HARKI
UNIVERSITY OF MINNESOTA, Minneapolis, United States
Targeted Protein Degradation with Small Molecules: how PROTACs Work (IL07)
Prof. Alessio CIULLI
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
The Ubiquitin System (IL08)
Prof. Huib OVAA
LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, The Netherlands
Small-Molecule Modulation of Cereblon Protein Level (OC01)
Mr Christian STEINEBACH
UNIVERSITY OF BONN, Bonn, Germany
Drugging Challenging E3 Ligases: A Novel Multidisciplinary Approach to Identify Small-Molecules that Bind FBW7 (OC02)
Ms Miriam MARTINEZ CARTRO
UNIVERSITY OF BARCELONA, Barcelona, Spain
Coffee Break and Exhibition
Session Chair
Prof. Andrzej BOJARSKI
INSTITUTE OF PHARMACOLOGY POLISH ACADEMY OF SCIENCES, Krakow, Poland
Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders (PL02)
Prof. Krzysztof PALCZEWSKI
CASE WESTERN RESERVE UNIVERSITY, Cleveland, United States
First Time Disclosure
The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders (IL09)
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Poster Session 1
(Posters with odd numbers)
G Protein-Coupled Receptors: the Structural Basis for their Pharmacology (IL10)
Dr Chris TATE
MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom
Design of Orexin-1 Receptor Selective Antagonists (IL11)
Dr Uta LESSEL
BOEHRINGER INGELHEIM, Biberach an der Riss, Germany
Next Generation GPR119 Agonists as Potential Treatment for Cardiometabolic Diseases (IL12)
Dr Lothar SCHWINK
SANOFI, Frankfurt Am Main, Germany
Coffee Break and Exhibition
Session Chair
Prof. Andrzej BOJARSKI
INSTITUTE OF PHARMACOLOGY POLISH ACADEMY OF SCIENCES, Krakow, Poland
Charting New Paths in Multi-Target Drug Discovery for Alzheimer’s Disease (IL13)
Prof. Maria Laura BOLOGNESI
UNIVERSITY OF BOLOGNA, Bologna, Italy
Multiple Targeting - The Histamine H3 Receptor Pharmacophore as Central Element (IL14)
Prof. Holger STARK
HEINRICH HEINE UNIVERSITY DÜSSELDORF, Duesseldorf, Germany
Chemical Biology for Drug Discovery: A Click and Play Approach Exemplified by ERK1/2 Probes (OC03)
Dr Charlotte GRIFFITHS-JONES
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
Identification and in-vivo Efficacy Studies of a Nicotinamide Derivative as Novel NNMT Inhibitor (OC04)
Dr Sven RUF
SANOFI-AVENTIS DEUTSCHLAND GMBH, Frankfurt am Main, Germany
Lunch and Exhibition
Session Chair
Prof. Katarzyna KIEC-KONONOWICZ
JAGIELLONIAN UNIVERSITY, Krakow, Poland
Cannabinoid Receptor Type 2 Modulation to Improve Outcomes for Cartilage Repair in the Osteoarthritic Joint (IL15)
Prof. Katarzyna STAROWICZ-BUBAK
INSTITUTE OF PHARMACOLOGY, POLISH ACADEMY OF SCIENCES, Krakow, Poland
Potential of Natural Cannabinoids and Synthetic Cannabinoids in Neuroprotection (IL16)
Prof. Rafael FRANCO
UNIVERSITY OF BARCELONA, Barcelona, Spain
Discovery of Best in-class, Novel, Selective, Potent and Peripheral FLT3 Inhibitors, a New Way to Treat Neuropathic Pain (OC05)
Dr Dominique SURLERAUX
BCI PHARMA, Liège, Belgium
The Discovery and Development of the Clinical FAAH Inhibitor JNJ-42165279 (OC06)
Prof. James BREITENBUCHER
UNIVERSITY OF CALIFORNIA SAN FRANCISCO, San Francisco, United States
Coffee Break and Exhibition
Next Generation Pain Therapeutics for the Opioid Crisis: Design of Bifunctional Nociceptin/Mu Opioid GPCR Ligands as non-Addicting Analgesics (PL03)
Dr Nurulain ZAVERI
ASTRAEA THERAPEUTICS, Mountain View, United States
Discovery of OAT-2068 - A Potent, Selective, Orally Bioavailable Inhibitor of Mouse Chitotriosidase and its In Vivo Activity in the Bleomycin-Induced Pulmonary Fibrosis Model in Mice (OC07)
Dr Agnieszka BARTOSZEWICZ
ONCOARENDI THERAPEUTICS SA, Warszawa, Poland
DPD-inspired Small Heterocyclic Libraries Characterized as Novel LsrK Kinase Inhibitors: an Opportunity to Fight Antimicrobial Resistance (OC08)
Dr Anna KARAWAJCZYK
SELVITA, Krakow, Poland
Poster Session 2
(Posters with even numbers)
Symposium Banquet
Session Chair
Prof. Edgars SUNA
LATVIAN INSTITUTE OF ORGANIC SYNTHESIS, Riga, Latvia
Protein-Ligand Interactions: How Medicinal Chemistry Contributes to the Understanding of Molecular Recognition (IL17)
Dr Marc NAZARE
FMP, Berlin, Germany
Adventures in Targeting Protein Lipdation: Breaking Drug Resistance Using Fragment Deconstruction and Chemical Biology (IL18)
Prof. Edward TATE
IMPERIAL COLLEGE LONDON, London, United Kingdom
Chemical Physiology of Antibody Conjugates and Natural Products (IL19)
"2018 MedChemComm Emerging Investigator Lectureship"
Dr Goncalo BERNARDES
INSTITUTO DE MEDICINA MOLECULAR, PORTUGAL & UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Coffee Break and Exhibition
Session Chair
Dr. Anders KARLÉN
UPPSALA UNIVERSITY, Uppsala, Sweden
Safety First: Covalent Inhibitors from a Safety Perspective (IL20)
Dr Mickael MOGEMARK
ASTRAZENECA, Mölndal, Sweden
Adventures in Functional Assignment and Inhibition of Metallo-Enzymes (IL21)
Prof. Christopher J. SCHOFIELD
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Lunch and Exhibition
Session Chair
Dr Carolyn DZIERBA
BRISTOL-MYERS SQUIBB, Wallingford, United States
Learning the Art of Chemical Synthesis with Deep Neural Networks and Discipline Scale Data (IL23)
Prof. Mark WALLER
UNIVERSITY OF WOLLONGONG, Wollongong, Australia
Applications of Artificial Intelligence in Drug Discovery – Separating Hype From Utility (IL24)
Dr Pat WALTERS
RELAY THERAPEUTICS, Cambridge, United States
Capturing and Applying Knowledge to Guide Compound Optimisation (OC10)
Mr Nick FOSTER
OPTIBRIUM, Cambridge, United Kingdom
Closing Remarks